• 華中科技大學(xué)同濟(jì)醫(yī)學(xué)院附屬協(xié)和醫(yī)院普外科（武漢430022）;

目的  研究尿激酶型纖溶酶原激活劑（uPA） mRNA在胃癌組織中的表達(dá)及其意義。
方法  應(yīng)用熒光定量RTPCR方法，分別檢測48例胃癌及其癌旁組織中uPA mRNA的表達(dá)，并結(jié)合其臨床病理特征進(jìn)行分析。
結(jié)果  48例胃癌組織及癌旁組織中，uPA mRNA表達(dá)陽性率分別為83.3%和25.0%。胃癌伴有淋巴結(jié)轉(zhuǎn)移和無淋巴結(jié)轉(zhuǎn)移者中,uPA mRNA表達(dá)陽性率分別為93.8%和62.5%，且uPA mRNA表達(dá)與胃癌浸潤程度呈正相關(guān)。
結(jié)論  uPA mRNA表達(dá)可作為判斷胃癌惡性程度及預(yù)后的指標(biāo)之一。

引用本文： 熊俊,鄭啟昌,宋自芳. 尿激酶型纖溶酶原激活劑mRNA在胃癌組織中的表達(dá)及其意義. 中國普外基礎(chǔ)與臨床雜志, 2004, 11(2): 116-118. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture [J]. Nature， 1976; 261(5561)∶595.
2. Chambers SK, Gertz RE Jr, Ivins CM, et al. The significance of urokinasetype plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer [Ｊ]. Cancer, 1995; 75(7)∶1627.
3. Konecny G, Untch M, Arboleda J, et al. Her2/neu and urokinasetype plasminogen activator and its inhibitor in breast cancer [Ｊ]. Clin Cancer Res, 2001; 7(8)∶2448.
4. Ito H, Yonemura Y, Fujita H, et al. Prognostic relevance of urokinasetype plasminogen activator (uPA) and plasminogen activator inhibitors PAI1 and PAI2 in gastric cancer [Ｊ]. Virchows Arch, 1996; 427(5)∶487.
5. Heiss MM, Babic R, Allgayer H, et al. Tumorassociated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinasetype plasminogen activator system [Ｊ]. J Clin Oncol, 1995; 13(8)∶2084.
6. Hsu DW, Efird JT, HedleyWhyte ET. Prognostic role of urokinasetype plasminogen activator in human gliomas [Ｊ]. Am J Pathol, 1995; 147(1)∶114.
7. Duggan C, Maguire T, McDermott E, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer [Ｊ]. Int J Cancer, 1995; 61(5)∶597.
8. Schneider J, Pollan M, Tejerina A, et al. Accumulation of uPAPAI1 complexes inside the tumour cells is associated with axillary nodal invasion in progesteronereceptorpositive early breast cancer [Ｊ]. Br J Cancer, 2003; 88(1)∶96.
9. Spyratos F, Bouchet C, Tozlu S, et al. Prognostic value of uPA, PAI1 and PAI2 mRNA expression in primary breast cancer [Ｊ]. Anticancer Res, 2002; 22(5)∶2997.
10. Casella R, Shariat SF, Monoski MA, et al. Urinary levels of urokinasetype plasminogen activator and its receptor in the detection of bladder carcinoma [Ｊ]. Cancer, 2002; 95(12)∶2494.
11. Tanaka N, Fukao H, Ueshima S, et al. Plasminogen activator inhibitor 1 in human carcinoma tissues [Ｊ]. Int J Cancer, 1991; 48(4)∶481.
12. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [Ｊ]. Genome Res, 1996; 6(10)∶986.
13. Swan DC, Tucker RA, Holloway BP, et al. A sensitive, typespecific, fluorogenic probe assay for detection of human papillomavirus DNA [Ｊ]. J Clin Microbiol, 1997; 35(4)∶886.
  1. 1. Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture [J]. Nature， 1976; 261(5561)∶595.
  2. 2. Chambers SK, Gertz RE Jr, Ivins CM, et al. The significance of urokinasetype plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer [Ｊ]. Cancer, 1995; 75(7)∶1627.
  3. 3. Konecny G, Untch M, Arboleda J, et al. Her2/neu and urokinasetype plasminogen activator and its inhibitor in breast cancer [Ｊ]. Clin Cancer Res, 2001; 7(8)∶2448.
  4. 4. Ito H, Yonemura Y, Fujita H, et al. Prognostic relevance of urokinasetype plasminogen activator (uPA) and plasminogen activator inhibitors PAI1 and PAI2 in gastric cancer [Ｊ]. Virchows Arch, 1996; 427(5)∶487.
  5. 5. Heiss MM, Babic R, Allgayer H, et al. Tumorassociated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinasetype plasminogen activator system [Ｊ]. J Clin Oncol, 1995; 13(8)∶2084.
  6. 6. Hsu DW, Efird JT, HedleyWhyte ET. Prognostic role of urokinasetype plasminogen activator in human gliomas [Ｊ]. Am J Pathol, 1995; 147(1)∶114.
  7. 7. Duggan C, Maguire T, McDermott E, et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer [Ｊ]. Int J Cancer, 1995; 61(5)∶597.
  8. 8. Schneider J, Pollan M, Tejerina A, et al. Accumulation of uPAPAI1 complexes inside the tumour cells is associated with axillary nodal invasion in progesteronereceptorpositive early breast cancer [Ｊ]. Br J Cancer, 2003; 88(1)∶96.
  9. 9. Spyratos F, Bouchet C, Tozlu S, et al. Prognostic value of uPA, PAI1 and PAI2 mRNA expression in primary breast cancer [Ｊ]. Anticancer Res, 2002; 22(5)∶2997.
  10. 10. Casella R, Shariat SF, Monoski MA, et al. Urinary levels of urokinasetype plasminogen activator and its receptor in the detection of bladder carcinoma [Ｊ]. Cancer, 2002; 95(12)∶2494.
  11. 11. Tanaka N, Fukao H, Ueshima S, et al. Plasminogen activator inhibitor 1 in human carcinoma tissues [Ｊ]. Int J Cancer, 1991; 48(4)∶481.
  12. 12. Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [Ｊ]. Genome Res, 1996; 6(10)∶986.
  13. 13. Swan DC, Tucker RA, Holloway BP, et al. A sensitive, typespecific, fluorogenic probe assay for detection of human papillomavirus DNA [Ｊ]. J Clin Microbiol, 1997; 35(4)∶886.